Multicentre, randomized, doubleblind, placebo-controlled trial of patients with recently diagnosed (<100 days) T1DM aged 3–45 years receiving 3 treatments (3 injections of 20 μg GAD-alum, 2 injections of 20 μg GAD-alum and 1 of alum, or 3 injections of alum). The gene discussed is GAD1; the disease is type 1 diabetes mellitus.